Hydroxybenzylidene-indolinones, c-di-AMP synthase inhibitors, have antibacterial and anti-biofilm activities and also re-sensitize resistant bacteria to methicillin and vancomycin†

Clement Opoku-Temeng,ac Neetu Dayal,ab Jacob Millerb and Herman O. Sintim*abd

c-di-AMP signaling regulates a myriad of physiological processes in Gram-positive bacteria and mycobacteria. c-di-AMP synthase (DAC) is essential in many human pathogens including Staphylococcus aureus, Listeria monocytogenes and Streptococcus pneumoniae and could become an important antibacterial drug target. In our continuing efforts to identify diverse DAC inhibitors, we uncovered hydroxybenzylidene-indolinones as new DAC inhibitors. Interestingly, these compounds also possess antibacterial activities and inhibit biofilm formation. Importantly, methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis could be re-sensitized to methicillin and vancomycin, respectively, by hydroxybenzylidene-indolinones.

Introduction

Each year millions of people become infected with drug-resistant bacteria and a significant number succumb to the pathogens. It has been estimated that if new antibacterial agents or adjuvants that re-sensitize resistant bacteria to traditional antibiotics are not developed/found, in the near future (by 2050) deaths due to bacterial infections will surpass 10 million. In light of this gloomy forecast, several groups have embarked on the search of essential pathways or proteins that could be targeted to develop a new generation of antibacterial agents. Recently, it was revealed that cyclic dimeric adenosine 3’,5’-monophosphate (c-di-AMP), initially discovered as a ligand bound to the DNA integrity scanning protein A (DisA) of Thermotoga maritima, is an important second messenger that is present in a myriad of clinically-relevant bacteria, including Staphylococcus aureus, Listeria monocytogenes, Streptococcus pyogenes, Mycobacterium tuberculosis, Chlamydia trachomatis among others. The physiological roles of c-di-AMP include peptidoglycan homeostasis, cell size regulation, fatty acid metabolism and transport, ion transport, biofilm formation and a host of other physiological processes (Fig. 1).

c-di-AMP is synthesized by diadenylate cyclases (DACs) from two molecules of ATP (Fig. 1). The DAc gene has been shown to be essential in some Gram-positive bacteria such as L. monocytogenes, S. aureus and S. pneumoniae, and this raises the potential that new drugs against these problematic bacteria could be found by screening for inhibitors of c-di-AMP synthesis. Of note c-di-AMP regulates cell wall homeostasis and because many antibiotics in clinical use also target the cell wall, it is anticipated that inhibitors of c-di-AMP could
potentiate the action of several cell wall-acting antibiotics. In a seminal study by Gründling, it was disclosed that depletion of intracellular c-di-AMP via the over-expression of a c-di-AMP PDE (GdpP) sensitized \textit{S. aureus} to the \beta-lactams oxacillin and penicillin \textit{G}. The \textit{gdpP} mutant strain was observed to have increased biofilm formation relative to the wildtype. Recently, another important work from Peng \textit{et al.} revealed that c-di-AMP regulates biofilm formation in \textit{S. pneumoniae}. These insights regarding the role of c-di-AMP in biofilm formation is interesting (it is known that biofilm bacteria are several orders of magnitude more resistant to antibiotics than planktonic bacteria) and could lead to new treatment paradigms against Gram-positive bacteria.  

Motivated by the central role played by c-di-AMP in some bacteria, especially \textit{S. aureus}, our group has been pursuing inhibitors of c-di-AMP synthesis with the hope that some of these compounds could be developed into antibacterial agents. Previously we revealed that bromophenol-TH, suramin and theaflavin digallate inhibit the prototypical c-di-AMP synthase, DisA. The first generation c-di-AMP synthase inhibitors are however not drug-like. For example suramin is polyanionic and suffers from poor cell penetration and the theaflavins are easily metabolized \textit{in vivo}. 3'-deoxyATP, a nucleotide analog was also identified as DAC inhibitor by Müller and others but this molecule also suffers from cell permeation issue (it is polyanionic as well). In our continuing efforts to identify cell-permeable compounds that also inhibit c-di-AMP synthesis, we identified a benzylidene-indolinone derivative as a cell permeable inhibitor of c-di-AMP synthesis. This molecule and analogs thereof demonstrate potent antibacterial properties and could synergize the action of other antibiotics.

**Results and discussion**

We previously used the coralyne assay to identify bromophenol-TH, suramin and theaflavin digallate as inhibitors of c-di-AMP synthase DisA from \textit{B. subtilis}. Based on the success of the coralyne assay, we screened a 20 000 compound library containing pharmacologically active compounds in order to identify cell permeable inhibitors of DAC. From the screen we identified a benzylidene-indolinone derivative, compound 1 (Fig. 2) as an inhibitor of c-di-AMP synthesis (Fig. S1A†). The DAC inhibition was confirmed using \textsuperscript{32}P-ATP assays (Fig. S1C†). Compound 1 (also called GW5074), was originally developed as a selective c-Ras inhibitor. It is non-toxic to mammalian cells and has been used in a few mouse studies without showing any adverse effects. Compound 1 possesses neuroprotective properties and in an \textit{in vivo} model of Huntington’s disease, it was shown to protect neurons \textit{via} resisting 3-NP-induced striatal neurodegeneration. 1 was also shown to suppress sidestream smoke-induced airway hyper responsiveness in mice. Based on its safety profile and hence high potential for clinical translation we proceeded to make a small library of this class of molecules following the synthetic strategy shown in Fig. 2A. A total of 15 analogs with subtle changes to the indolinone and benzylidene moieties were easily synthesized (Fig. 2B) and screened for DAC inhibition. The “hit” compound 1 is decorated with an iodo group at the 5-position of the indolinone. Compounds 2–9 were designed to identify which substituent at the 5-position of the indolinone core was optimal for DAC inhibition. Compound 2 did not have any substitution at position 5, whereas compounds 3 and 4 contained bromo and trifluoromethyl groups (both groups are similarly as hydrophobic as the iodo group). Compounds 3, 4, 5, 6 and 7 were 5-bromo, 5-trifluoromethyl, 5-hydroxy, 5-cyano and 5-amino substitutions respectively. Compounds 5–9 contained the polar groups OH (5), CN (6), NH\textsubscript{2} (7), CO\textsubscript{2}Me (8) and CO\textsubscript{2}H (9). We expected the ester group to be converted into the acid moiety inside the cell, although the ester compound (a prodrug) could have different permeation properties than the acid. Compound 14 contained an iodo moiety at the 6-position of the indolinone and is ideal for comparing 5- vs 6-substitutions of the indolinone. To investigate the importance of the bromo groups on the benzylidene portion of the molecule, we synthesized compounds 10–12 whereby the bromo groups were replaced with H, F and Cl. Finally, the importance of the hydroxyl group at the 4-position of the benzylidene was investigated by making compounds 13 and 15, which did not contain a phenol or compound 16, which had the OH group moved from the 4-position to the 2-position on the benzylidene. With these compounds in hand, we proceeded to investigate which compounds inhibited DisA, using the coralyne assay. 

DAC activity assay, in the presence of the synthesized compounds revealed that substitution of the indolinone moiety with hydrophilic groups (OH (5), CN (6), NH\textsubscript{2} (7), CO\textsubscript{2}Me (8) and CO\textsubscript{2}H (9)) lead to compounds that were weak DAC inhibitors (Fig. 3A). On the contrary, substitution of indolinone moiety with iodo or CF\textsubscript{3} group at the 5-position (compounds 1, 4 or 10) afforded potent inhibitors of DAC. At 20 \textmu M, compounds 1 and...
indolinones compounds on bacterial viability. Initially, we screened the compounds against *S. aureus* (ATCC 25923) and *E. coli* (ATCC 25923) (as representative Gram-positive and Gram-negative bacteria). The bacteria were cultured in the presence of 16 μg mL⁻¹ of the hydroxybenzylidene-indolinones in Mueller Hinton broth (MHB) for 24 h at 37 °C with 250 rpm shaking. Post incubation, we measured the optical density at 600 nm (OD₆₀₀) of the cultures. For each bacterial species, an equivalent amount of DMSO, not exceeding 0.1% was used as negative control. Compounds 1, 2, 3, 4, 10 and 14 (but not compounds 5–9 or 11–13 or 15–16 or 5-iodoindolin-2-one) significantly inhibited the growth of *S. aureus*. None of the compounds affected *E. coli* growth (Fig. 4 and S3–S5†).

To rule out the possibility that the lack of activity against *E. coli* was not due to permeation issue, we also investigated the activity of compound 1 (16 μg mL⁻¹) in the presence of the MIC value of colistin (0.03125 μg mL⁻¹). Treating *E. coli* with the MIC value of colistin (a non-toxic concentration) would make the bacteria permeable to compounds. Even in the presence of colistin, compound 1 did not inhibit the growth of *E. coli* (Fig. S5†). This experiment suggests that the hydroxybenzylidene-indolinones work via a Gram-positive specific mechanism. For the active compounds, we expanded the panel of bacteria to include *L. monocytogenes* (ATCC 19115) and *Pseudomonas aeruginosa* (ATCC 27853) and also observed that they were active against the Gram-positive *L. monocytogenes* but not against the Gram-negative *P. aeruginosa* (Fig. 4).

Having established the susceptibility of bacteria to the compounds, we sought to determine their minimum inhibitory concentration (MIC). For this we also included antibiotic resistant strains MRSA ATCC 33592 and vancomycin-resistant *E. faecalis* (ATCC 51575). The MIC values obtained are as shown in Table 1.

All compounds had good MIC values against *S. aureus* and MRSA, ranging from 4 μg mL⁻¹ to 16 μg mL⁻¹ but not against VRE faecalis. Compounds 4, 10 and 14 appeared to be particularly potent against *L. monocytogenes*, with MIC values ranging from 2 μg mL⁻¹ to 4 μg mL⁻¹ (Table 1).

As earlier stated, biofilm-associated infections continue to be a major public health threat. Biofilms in general are difficult to treat, due in part to the reduced penetration of antibiotics into...
Very recently Peng et al. demonstrated that the deletion of pdeA, gene that encodes the S. pneumoniae PDE resulted in an increased S. pneumoniae biofilm formation. Also, Gründling and colleagues showed that in S. aureus, deletion of GdpP (PDE) resulted in increased biofilm formation relative to wildtype. These observations implicated c-di-AMP signaling in regulating biofilm formation. A report by the United States Centers for Disease Control and Prevention in 2013, characterized MRSA as being at the threat level of serious; implying that these require immediate attention. Staphylococcal infections are problematic in the healthcare setting primarily as a result of biofilm formation on host tissues, implants and medical devices. Others have pursued small molecules that inhibit MRSA biofilm formation. Motivated by these studies, we tested all 16 compounds for their effect on MRSA biofilm formation. The microtiter plate biofilm formation was employed using compounds at concentrations ranging from 16 μg mL⁻¹ to 0.03125 μg mL⁻¹. We observed that 6 compounds (1, 2, 3, 4, 10 and 14) potently inhibited biofilm formation (Fig. 5A). The IC₅₀ values for biofilm inhibition for the compounds were 0.19 μg mL⁻¹ for compound 1; 0.11 μg mL⁻¹ for compound 2; 0.81 μg mL⁻¹ for compound 3; 0.69 μg mL⁻¹ for compound 4; 0.70 μg mL⁻¹ for compound 10 and 0.40 μg mL⁻¹ for compound 14 (Fig. 5B and C). The concentration of maximum biofilm inhibition, IC₁₀₀, (Fig. 5C) were observed to be similar to the MIC values (Table 1), implying that the anti-biofilm activities were derived from growth inhibition.

‘Resurrecting’ antibiotics that have been rendered ineffective due to resistance by combining them with small molecules “adjuvants” is now being pursued as a strategy to combat antibiotic resistance. Recently several groups have reported several small molecules that could re-sensitize MRSA or VRE to β-lactams or vancomycin respectively.

Table 1 MIC values of active hydroxybenzylidene-indolinones against select bacteria

| Test compounds | MIC (µg mL⁻¹) | S. aureus | MRSA | L. monocytogenes | VRE faecalis |
|----------------|---------------|----------|------|-----------------|-------------|
| 1              | 8             | 8        | 8    | 16              |             |
| 2              | 8             | 16       | 16   | 128             |             |
| 3              | 8             | 8        | 16   | >128            |             |
| 4              | 8             | 4        | 2    | 32              |             |
| 10             | 8             | 4        | 2    | 64              |             |
| 14             | 4             | 4        | 4    | >128            |             |
| Vancomycin     | 1             | 1        | 1    | >128            |             |
| Methicillin    | 2             | >128     | ND   | ND              |             |

a ND represents not determined.

Fig. 5 Inhibition of MRSA ATCC 33592 biofilms. (A) Representative wells of crystal violet stained biofilms of MRSA ATCC 33592. Compounds tested are as labelled to the left and the concentrations used are indicated on top. (B) IC₅₀ curves and (C) table of IC₅₀ and IC₁₀₀ values of biofilm inhibition by hydroxybenzylidene-indolinones. Every data point is the mean of 4 replicates and error bars represent the standard error of the mean. Plots were generated using GraphPad Prism version 5 statistical software.
Having observed that the compounds were active against MRSA and VRE faecalis, we investigated the ability of hydroxybenzylidene-indolinones to re-sensitize MRSA and VRE faecalis to methicillin and vancomycin respectively. MRSA is resistant to methicillin with an MIC of greater than 128 \( \mu \text{g} \text{mL}^{-1} \). In the presence of 2 \( \mu \text{g} \text{mL}^{-1} \) of compound 1 and 4, an MIC of 2 \( \mu \text{g} \text{mL}^{-1} \) was obtained for methicillin against MRSA; signifying a fold change in MIC of greater than 64-fold (Table 2). Compounds 3 and 10 also reduced the MIC of methicillin by greater than 32-fold from >128 \( \mu \text{g} \text{mL}^{-1} \) to 4 \( \mu \text{g} \text{mL}^{-1} \).

Similarly, the MIC of vancomycin for VRE faecalis was determined to be greater than 128 \( \mu \text{g} \text{mL}^{-1} \). When combined with compound 1 at 4 \( \mu \text{g} \text{mL}^{-1} \) (1/4 MIC) we observed a greater than 64-fold improvement in MIC of vancomycin (Table 2). On their own, compounds 3, 4, 10 and 14 have weak activity against VRE faecalis (Table 1). Interestingly, at 8 \( \mu \text{g} \text{mL}^{-1} \) of 3, 4 and 10, the MIC of vancomycin improved by greater than 64-fold. At that same concentration we observed that compound 14 could reduce the MIC of vancomycin for VRE faecalis from >128 \( \mu \text{g} \text{mL}^{-1} \) to 1 \( \mu \text{g} \text{mL}^{-1} \) (Table 2). In both instances, we observed that compound 2 could not potentiate the activity of either methicillin or vancomycin.

The enzyme used in this study were expressed from *E. coli* BL21 (DE3) cells harboring specific plasmids. Briefly, protein expression was induced at OD\(_{600}\) of 0.6 by the addition of 1 mM isopropyl \( \beta \)-D-1-thiogalactopyranoside (IPTG) and the culture temperature reduced to 16 °C. Expression was performed for 18 hours after which cultures were centrifuged at 5000 rpm for 15 min at 4 °C. The cell pellets were then resuspended in lysis buffer (50 mM sodium phosphate buffer, pH 8.0, 300 mM NaCl) and lysed by sonication. The supernatant of the lysate was collected by centrifugation and proteins were purified by nickel affinity chromatography. Aliquots of purified proteins were stored in 10% glycerol at −80 °C.

### Methods

#### General synthesis of hydroxybenzylidene-indolinones

For the synthesis and characterization of hydroxybenzylidene-indolinones, see ESI†

#### Bacterial strains and growth conditions

Standard strains of *S. aureus* (ATCC 25923 and MRSA ATCC 33592), *L. monocytogenes* ATCC 19115, vancomycin-resistant *E. faecalis* ATCC 51575, *E. coli* ATCC 25922 and *P. aeruginosa* ATCC 27853 were routinely cultured in Mueller–Hinton broth 37 °C unless otherwise stated.

#### Protein expression and purification

The screening was performed using the coralyne assay as previously described. Briefly, the compounds were stored as 10 mM DMSO stock solutions. Aliquots of the compounds (20 \( \mu \text{M} \)) or DMSO were added to a reaction mixture containing 10 \( \mu \text{M} \) coralyne, 300 \( \mu \text{M} \) ATP and 3 mM KI in a 40 mM Tris–HCl pH 7.5, 100 mM NaCl and 10 mM MgCl\(_2\) reaction buffer. We then initiated the reactions by adding DisA at 0.5 \( \mu \text{M} \) and incubated at 30 °C. The change in coralyne fluorescence at 475 nm when excited at 420 nm was monitored on a BioTek Cytation 5 Cell Imaging Multi-Mode Reader for 30 min. Compounds that reduced the fluorescence of coralyne were selected and further analysed by HPLC. The reaction components (as above but without coralyne and KI) were mixed up 30 °C. After 2 hours, the reaction was heated at 95 °C for 5 min and the precipitated proteins were filtered off. Components of the filtrate were then analyzed on a COSMOSIL C18-MS-II Packed column (5 \( \mu \text{m} \)) using 0.1 M TEAA in water (Buffer A) and acetonitrile (Buffer B). The samples will be eluted with 99% → 87% Buffer A at 0 to 16 min, 87% → 10% Buffer A at 16 to 22 min and kept at 10% Buffer A till 25 min, detecting signals at room temperature with a 260 nm UV detector.

For radioactive TLC assay, compound 1 (20 \( \mu \text{M} \)) was incubated with 100 \( \mu \text{M} \) ATP, 11.1 nM \(^{32}\text{P}-\text{ATP}\) and DisA (0.25 \( \mu \text{M} \)) in the same reaction buffer as above for 2 h. An equal volume of DMSO was used as control. Aliquots of the reaction were spotted on TLC plates and separated using a saturated \((\text{NH}_4)_2\text{SO}_4\) and

### Conclusions

In our continual efforts to identify compounds that inhibit cyclic dinucleotide signalings, we uncovered hydroxybenzylidene-indolinones as new inhibitors of c-di-AMP synthesis *in vitro*. Interestingly these compounds could sensitize resistant bacteria to methicillin and vancomycin. Further works in our laboratory are focused on mode of action studies and also lead optimization to arrive at more potent analogs of the compounds reported in this manuscript.
1.5 M KH₂PO₄ buffer. The spots were imaged on a Typhoon FLA 9500 scanner.

Effect of hydroxybenzylidene-indolinones on bacterial viability

The effect on the growth of S. aureus, L. monocytogenes, P. aeruginosa and E. coli strains was determined by assessing culture turbidity after 24 h. Briefly, overnight cultures of the bacteria were diluted 1:10,000 in MHB and cultured for 2–3 h (early exponential) at 37°C. Aliquots were then dispensed into sterile glass tubes containing stock solutions of compounds in DMSO to yield a final concentration of 16 µg mL⁻¹. For the E. coli with colistin experiment, 0.03125 µg mL⁻¹ colistin was added to the cultures before adding either compound 1 or an equal volume of DMSO. The cultures were incubated at 37°C for 24 h and the OD₆₀₀ of each culture was measured using a BioTek Cytation 5 Cell Imaging Multi-Mode Reader.

Minimum inhibitory concentration determination

The MIC of active compounds were determined according to the guideline of the CLSI. Cation-adjusted Mueller–Hinton broth was routinely used. Aliquots of 0.5 McFarland standardized inoculum were dispensed into wells of 96 well plate to 5 × 10⁵ CFU mL⁻¹ with test compounds at a final concentrations from 128 µg mL⁻¹ to 0.5 µg mL⁻¹. Vancomycin and methicillin were routinely used as the antibiotic controls and were tested within the same range of concentrations. The cultures were incubated at 35°C for 20 h. Guided by the MIC values of the compounds and antibiotics, we calculated the fold change for wells with no visible turbidity.

Biofilm studies

MRSA biofilm inhibition was performed in tissue culture treated 96 well plates (CellTreat Sci. Pdt, MA, USA). Overnight cultures of MRSA ATCC 33592 were diluted 1:100 in fresh tryptic soy broth (TSB) supplemented with 1% glucose. The diluted culture was inoculated into wells with compound (at 16 µg mL⁻¹ to 0.03125 µg mL⁻¹). The plates were incubated at 37°C for 24 h after which the medium was carefully removed and the unattached cells washed away. The biofilms were stained with 0.1% crystal violet for 30 min. The crystal violet was removed and wells washed until no crystal violet was present in the wash. The dye was solubilized with 100% ethanol for 1 h and the unattached cells washed away. The biofilm stain was quantified by measuring absorbance at 595 nm on a BioTek Cytation 5 Cell Imaging Multi-Mode Reader. The A₅₉₅ value for any absorbance reading, A was normalized to the no compound (A₇) and broth (A₀) controls using the equation

\[ \text{% normalized } A_{595} = \left( \frac{A - A_0}{A_7 - A_0} \right) \times 100 \]

Antibiotic-hydroxybenzylidene-indolinones combination analysis

We used the standard checkerboard assay to determine the ability of the hydroxybenzylidene-indolinones to potentiate the activity of antibiotics (methicillin and vancomycin). Briefly, the antibiotics were serially diluted along the abscissa of a 96 well microtiter plate to achieve a starting concentration of 128 µg mL⁻¹ whilst the hydroxybenzylidene-indolinones were diluted along the ordinate. An inoculum equal to a 0.5 McFarland turbidity standard was prepared for both MRSA ATCC 33592 and VRE faecalis ATCC 51575 in sterile saline. Aliquots of the standardized inoculum were dispensed into the microtiter plates to give 5 × 10⁵ CFU mL⁻¹. The plates were then incubated at 35°C for 20 h. Guided by the MIC values of the compounds and antibiotics, we calculated the fold change for wells with no visible turbidity.

Acknowledgements

This work was funded by the National Science Foundation (CHE1307218 and CHE1636752), Purdue University. We thank Dr Karl-Peter Hopfen and Dr Angelika Gründling for plasmids encoding DisA.

Notes and references

1. M. E. de Kraker, A. J. Stewardson and S. Harbarth, PLoS Med., 2016, 13, e1002184.
2. G. D. Wright, ACS Infect. Dis., 2015, 1, 80–84.
3. G. Witte, S. Hartung, K. Buettner and K.-P. Hopfen, Mol. Cell, 2008, 30, 167–178.
4. R. M. Corrigan, J. C. Abbott, H. Burhenne, V. Kaever and A. Gründling, PLoS Pathog., 2011, 7, e1002217.
5. J. J. Woodward, A. T. Iavarone and D. A. Portnoy, Science, 2010, 328, 1703–1705.
6. T. Kamengaya, K. Kuroda and Y. Hayakawa, Nagoya J. Med. Sci., 2011, 73, 49–57.
7. Y. Bai, J. Yang, X. Zhou, X. Ding, L. E. Eisele and G. Bai, PLoS One, 2012, 7, e35206.
8. J. R. Barker, B. J. Koestler, V. K. Carpenter, D. L. Burdette, C. M. Waters, R. E. Vance and R. H. Valdivia, mBio, 2013, 4, e00018-13.
9. Y. Luo and J. D. Helmann, Mol. Microbiol., 2012, 83, 623–639.
10. C. E. Witte, A. T. Whiteley, T. P. Burke, J.-D. Sauer, D. A. Portnoy and J. J. Woodward, mBio, 2013, 4, e00282-13.
11. L. Zhang, W. Li and Z.-G. He, J. Biol. Chem., 2013, 288, 3085–3096.
12. Y. Bai, J. Yang, T. M. Zarrella, Y. Zhang, D. W. Metzger and G. Bai, J. Bacteriol., 2014, 196, 614–623.
13. X. Peng, Y. Zhang, G. Bai, X. Zhou and H. Wu, Mol. Microbiol., 2016, 99, 945–959.
14. J. H. Song, K. S. Ko, J. Y. Lee, J. Y. Baek, W. S. Oh, H. S. Yoon, J. Y. Jeong and J. Chun, Mol. Cells, 2005, 19, 365–374.
15. R. R. Chaudhuri, A. G. Allen, P. J. Owen, G. Shalom, K. Stone, M. Harrison, T. A. Burgis, M. Lockyer, J. Garcia-Lara,
S. J. Foster, S. J. Pleasance, S. E. Peters, D. J. Maskell and I. G. Charles, *BMC Genomics*, 2009, **10**, 291.

16 C. T. Walsh and T. A. Wencewicz, *J. Antibiob.,* 2014, **67**, 7–22.
17 C. Opoku-Temeng, J. Zhou, Y. Zheng, J. M. Su and H. O. Sintim, *Chem. Commun.*, 2016, **52**, 9327–9342.

18 Y. Zheng, J. Zhou, D. A. Sayre and H. O. Sintim, *Chem. Commun.*, 2014, **50**, 11234–11237.

19 C. Opoku-Temeng and H. O. Sintim, *Chem. Commun.*, 2016, **52**, 3754–3757.

20 C. Opoku-Temeng and H. O. Sintim, *Sci. Rep.*, 2016, **6**, 25445.
21 J. D. Lambert and C. S. Yang, *J. Nutr.*, 2003, **133**, S3262S–S3267S.

22 M. Müller, T. Deimling, K. P. Hopfner and G. Witte, *Biochem. J.*, 2015, **469**, 367–374.

23 J. Zhou, D. A. Sayre, Y. Zheng, H. Szmacinski and H. O. Sintim, *Anal. Chem.*, 2014, **86**, 2412–2420.
24 P. C. Chin, L. Liu, B. E. Morrison, A. Siddiq, R. R. Ratan, T. Bottiglieri and S. R. D'Mello, *J. Neurochem.*, 2004, **90**, 595–608.

25 Y. Lei, Y. X. Cao, C. B. Xu and Y. Zhang, *Respir. Res.*, 2008, **9**, 71.

26 D. Davies, *Nat. Rev. Drug Discovery*, 2003, **2**, 114–122.

27 CDC, Antibiotic resistance threats in the United States, Report CS239559-B, 2013, [http://www.cdc.gov/drugresistance/threats-report-2013](http://www.cdc.gov/drugresistance/threats-report-2013).

28 J. L. Lister and A. R. Horswill, *Front. Cell. Infect. Microbiol.*, 2014, **4**, 178.

29 R. J. Worthington, J. J. Richards and C. Melander, *Org. Biomol. Chem.*, 2012, **10**, 7457–7474.

30 A. A. Yeagley, Z. Su, K. D. McCullough, R. J. Worthington and C. Melander, *Org. Biomol. Chem.*, 2013, **11**, 130–137.

31 G. A. O'Toole, *J. Visualized Exp.*, 2011, **47**, e2437.

32 L. Kalan and G. D. Wright, *Expert Rev. Mol. Med.*, 2011, **13**, e5.

33 R. Laxminarayan, A. Duse, C. Wattal, A. K. Zaidi, H. F. Werthein, N. Sumpradit, E. Vlieghe, G. L. Hara, I. M. Gould, H. Goossens, C. Greko, A. D. So, M. Bigdeli, G. Tomson, W. Woodhouse, E. Ombaka, A. Q. Peralta, F. N. Qamar, F. Mir, S. Kariuki, Z. A. Bhutta, A. Coates, R. Bergstrom, G. D. Wright, E. D. Brown and O. Cars, *Lancet Infect. Dis.*, 2013, **13**, 1057–1098.

34 G. D. Wright, *Trends Microbiol.*, 2016, **24**, 862–871.

35 T. L. Harris, R. J. Worthington and C. Melander, *Angew. Chem., Int. Ed. Engl.*, 2012, **51**, 11254–11257.

36 H. Yamazaki, K. Nonaka, R. Masuma, S. Omura and H. Tomoda, *J. Antibiot.*, 2009, **62**, 431–434.

37 C. M. Brackett, R. J. Melander, I. H. An, A. Krishnamurthy, R. J. Thompson, J. Cavanagh and C. Melander, *J. Med. Chem.*, 2014, **57**, 7450–7458.

38 G. Chiosis and I. G. Boneca, *Science*, 2001, **293**, 1484–1487.

39 Y. Zheng, G. Tsuji, C. Opoku-Temeng and H. O. Sintim, *Chem. Sci.*, 2016, **7**, 6238–6244.

40 G. Orhan, A. Bayram, Y. Zer and I. Balci, *J. Clin. Microbiol.*, 2005, **43**, 140–143.